New MR perfusion features in primary central nervous system lymphomas: pattern and prognostic impact
- 229 Downloads
Some MR perfusion features predict overall survival (OS) and progression-free survival (PFS) in glioblastomas. Prognostic value of MR perfusion in primary CNS lymphomas (PCNSL) remains unexplored being the aim of this investigation.
We retrospectively analyzed 3Tesla dynamic susceptibility contrast MR perfusion in 37 pre-surgical PCNSL for normalized regional cerebral blood volume rCBVmean and rCBVmax and for a PCNSL-typical shoulder-like increase of the time–signal intensity curve (“TSIC-shoulder”), indicating moderate vessel permeability. These MR perfusion features, tumor and edema size, number of lesions and patient characteristics were correlated with OS and PFS.
Only patient’s age was prognostic for OS (p = 0.0037) and PFS (p = 0.0088). 23 PCNSL had the TSIC-shoulder, a middle-sized diameter (39.5 ± 10.8 mm), volume (15.7 ± 11.3 ml), peritumoral edema (23 ± 8.7 mm) and moderately increased rCBVmean and rCBVmax (1.7 ± 0.5; 3.9 ± 1.2). Seven PCSNL with the TSIC-shoulder presented a sun-like pattern (“rCBV-sun”) with a rim of marginally high rCBV. These unifocal PCNSL were larger (43 ± 11.2 mm; 25.62 ± 19.2 ml), with more peritumoral edema (32.8 ± 7.6 mm) and lower CBVmean (0.8 ± 0.3) and rCBVmax (2.2 ± 0.7), compared to the remaining six multifocal PCNSL without the TSIC-shoulder (26.3 ± 8.3 mm; 4.7 ± 4 ml; 16.3 ± 6.4 mm; 2.4 ± 1.6; 4.4 ± 2.3).
Only patient age was predictive for OS and PFS of PCNSL; MR perfusion parameters and features were not. Most PCNSL revealed the TSIC-shoulder, moderate size, peritumoral edema and rCBV increase. However, larger, solitary PCNSL additionally had a rCBV-sun pattern and more edema, maybe due to a centrifugal vessel proliferation, whereas smaller, multifocal PCNSL contain apparently more concentrated and less permeable blood vessels represented by higher rCBV, no TSIC-shoulder and less edema.
KeywordsPrimary CNS lymphoma MR perfusion rCBV Overall survival Progression-free survival Prognostic value
M.M. would like to thank the Luxembourg National Research Fond (FNR) for the support (FNR PEARL P16/BM/11192868 Grant).
The study was not funded by external sources.
Compliance with ethical standards
Conflicts of interest
The authors declared that they have no conflict of interest.
Ethical standard statement
This study was approved by the institutional review board at Frankfurt Goethe University and was performed in accordance with the ethical standards for human subjects research. For this type of study formal consent is not required.
- 3.O’Neill BP, Decker PA, Tieu C, Cerhan JR (2013) The changing incidence of primary central nervous system lymphoma is driven primarily by the changing incidence in young and middle-aged men and differs from time trends in systemic diffuse large B-cell non-Hodgkin’s lymphoma. Am J Hematol 88:997–1000. https://doi.org/10.1002/ajh.23551 CrossRefPubMedPubMedCentralGoogle Scholar
- 26.Kickingereder P, Wiestler B, Sahm F et al (2014) Primary central nervous system lymphoma and atypical glioblastoma: multiparametric differentiation by using diffusion-, perfusion-, and susceptibility-weighted MR imaging. Radiology 272:843–850. https://doi.org/10.1148/radiol.14132740 CrossRefPubMedGoogle Scholar
- 27.Wang S, Kim S, Chawla S et al (2011) Differentiation between glioblastomas, solitary brain metastases, and primary cerebral lymphomas using diffusion tensor and dynamic susceptibility contrast-enhanced MR imaging. AJNR Am J Neuroradiol 32:507–514. https://doi.org/10.3174/ajnr.A2333 CrossRefPubMedGoogle Scholar
- 28.Toh CH, Wei K-C, Chang C-N et al (2013) Differentiation of primary central nervous system lymphomas and glioblastomas: comparisons of diagnostic performance of dynamic susceptibility contrast-enhanced perfusion MR imaging without and with contrast-leakage correction. AJNR Am J Neuroradiol 34:1145–1149. https://doi.org/10.3174/ajnr.A3383 CrossRefPubMedGoogle Scholar
- 29.Nakajima S, Okada T, Yamamoto A et al (2015) Primary central nervous system lymphoma and glioblastoma: differentiation using dynamic susceptibility-contrast perfusion-weighted imaging, diffusion-weighted imaging, and (18)F-fluorodeoxyglucose positron emission tomography. Clin Imaging 39:390–395. https://doi.org/10.1016/j.clinimag.2014.12.002 CrossRefPubMedGoogle Scholar
- 33.Schlegel U, Illerhaus G (2015) Leitlinien für Diagnostik und Therapie in der Neurologie: Primäre ZNS-Lymphome (PZNSL). https://www.dgn.org/leitlinien/2984-ll-78-primaere-zns-lymphome-pznsl. Accessed 13 Dec 2017
- 36.Illerhaus G, Muller F, Feuerhake F et al (2008) High-dose chemotherapy and autologous stem-cell transplantation without consolidating radiotherapy as first-line treatment for primary lymphoma of the central nervous system. Haematologica 93:147–148. https://doi.org/10.3324/haematol.11771 CrossRefPubMedGoogle Scholar
- 37.Ferreri AJM, Cwynarski K, Pulczynski E et al (2016) Chemoimmunotherapy with methotrexate, cytarabine, thiotepa, and rituximab (MATRix regimen) in patients with primary CNS lymphoma: results of the first randomisation of the International Extranodal Lymphoma Study Group-32 (IELSG32) phase 2 trial. Lancet Haematol 3:e217–e227. https://doi.org/10.1016/S2352-3026(16)00036-3 CrossRefPubMedGoogle Scholar
- 44.Gutman SI, Piper M, Grant MD et al (2013) Progression-free survival: what does it mean for psychological well-being or quality of life? Agency for Healthcare Research and Quality, Rockville. https://www.ncbi.nlm.nih.gov/books/NBK137759. Accessed 10 Dec 2017
- 51.Xing Z, You RX, Li J et al (2014) Differentiation of primary central nervous system lymphomas from high-grade gliomas by rCBV and percentage of signal intensity recovery derived from dynamic susceptibility-weighted contrast-enhanced perfusion MR imaging. Clin Neuroradiol 24:329–336. https://doi.org/10.1007/s00062-013-0255-5 CrossRefPubMedGoogle Scholar